16346 Peak Pruritus Numeric Rating Scale response with abrocitinib in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial

Eric L Simpson; Sonja Ständer; Gil Yosipovitch; Michael C Cameron; Marco DiBonaventura; David Williams; Svitlana Tatulych; Chudy Nduaka; Hernan Valdez

doi:10.1016/j.jaad.2020.06.330

Journal article

16346 Peak Pruritus Numeric Rating Scale response with abrocitinib in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial

Eric L Simpson, Sonja Ständer, Gil Yosipovitch, Michael C Cameron, Marco DiBonaventura, David Williams, Svitlana Tatulych, Chudy Nduaka and Hernan Valdez

Journal of the American Academy of Dermatology, Vol.83(6), pp.AB61-AB61

2020-12

DOI: https://doi.org/10.1016/j.jaad.2020.06.330

Metrics

2 Record Views

Details

Title: 16346 Peak Pruritus Numeric Rating Scale response with abrocitinib in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial
Creators: Eric L Simpson - Oregon Health & Science University
Sonja Ständer - Center for Chronic Pruritus, University Hospital of Münster, Germany
Gil Yosipovitch - Miller School of Medicine, Miami
Michael C Cameron
Marco DiBonaventura
David Williams - Syneos Health
Svitlana Tatulych
Chudy Nduaka
Hernan Valdez
Publication Details: Journal of the American Academy of Dermatology, Vol.83(6), pp.AB61-AB61
Publisher: Elsevier Inc
Academic Unit: Miller School of Medicine; UMMG Dept of Dermatology & Cutaneous Surgery
Language: English
Resource Type: Journal article
Record Identifier: 991031713507702976